Cargando…

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms

The purpose of this study was to compare the performance of anti-factor Xa concentration versus activated partial thromboplastin time (aPTT) monitoring with multiple indication-specific heparin nomograms. This was a prospective, nonrandomized study with historical control at a large academic medical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whitman-Purves, Emily, Coons, James C., Miller, Taylor, DiNella, Jeannine V., Althouse, Andrew, Schmidhofer, Mark, Smith, Roy E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714688/ https://www.ncbi.nlm.nih.gov/pubmed/29212374 http://dx.doi.org/10.1177/1076029617741363

Ejemplares similares

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study
por: Saito, Tomoyo, et al.
Publicado: (2023)

Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
por: Monteagudo-Vela, María, et al.
Publicado: (2021)

Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay
por: Billoir, Paul, et al.
Publicado: (2022)

The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy
por: Lapić, Ivana, et al.
Publicado: (2021)

A Recurrent Neural Network Model for Predicting Activated Partial Thromboplastin Time After Treatment With Heparin: Retrospective Study
por: Boie, Sebastian Daniel, et al.
Publicado: (2022)

The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time
por: Samara, Evangelia, et al.
Publicado: (2021)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial
por: Aubron, Cécile, et al.
Publicado: (2023)

International normalized ratio and activated partial thromboplastin time testing
por: Chornenki, Nicholas L. J., et al.
Publicado: (2022)

Heparin: Masking of overt disseminated intravascular coagulation, activated partial thromboplastin time prolonged and rebound effect in the form of coagulation disorders: case report
Publicado: (2020)

Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
por: Xu, Lengnan, et al.
Publicado: (2023)

Comparative analysis on characteristics of two activated partial thromboplastin time reagents
por: Yasui, Yutaro, et al.
Publicado: (2022)

Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!
por: Santoro, Rita Carlotta, et al.
Publicado: (2023)

The Problem of the Lipoid Thromboplastins
por: Milstone, J. H.
Publicado: (1950)

Lipoid Thromboplastin and Trypsin
por: Milstone, J. H., et al.
Publicado: (1954)

Activated Partial Thromboplastin Time and Mortality in Coronary Artery Bypass Grafting Patients
por: Zhang, HuanRui, et al.
Publicado: (2022)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
por: Nguyen, Tung Phi, et al.
Publicado: (2021)

Diabetes Mellitus Is Associated with Shortened Activated Partial Thromboplastin Time and Increased Fibrinogen Values
por: Zhao, Ying, et al.
Publicado: (2011)

Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time
por: Spencer, Akpan, et al.
Publicado: (2011)

Coronary Artery Disease Presentation and Its Association with Shortened Activated Partial Thromboplastin Time
por: Sotoudeh Anvari, Maryam, et al.
Publicado: (2018)

Falsely prolonged activated partial thromboplastin time – a pre- and post-analytical issue
por: Gils, Charlotte, et al.
Publicado: (2018)

An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform
por: Katayama, Haruna, et al.
Publicado: (2018)

Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
por: Guy, Susan, et al.
Publicado: (2021)

An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
por: Teng, Yuan, et al.
Publicado: (2022)

A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
por: Liu, Ying, et al.
Publicado: (2022)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

Activated partial thromboplastin time waveform analysis as specific sepsis marker in cardiopulmonary bypass surgery
por: Schneider, Christian P, et al.
Publicado: (2010)

A Patient with a Prolonged Activated Partial Thromboplastin Time and a Deep Intracerebral Haemorrhage
por: Schindhelm, Roger K., et al.
Publicado: (2012)

Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus
por: Sapkota, Binaya, et al.
Publicado: (2013)

Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients
por: Tokutake, Takayoshi, et al.
Publicado: (2016)

Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients
por: Moiz, Bushra, et al.
Publicado: (2021)

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population
por: Zhang, Fan, et al.
Publicado: (2022)

Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients
por: Brakta, Charlyne, et al.
Publicado: (2023)

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021)

Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition
por: Rashid, Qudsia, et al.
Publicado: (2014)

Normalization of Activated Partial Thromboplastin Time Correlates with Low Levels of Dabigatran in a Patient with Severe Sepsis
por: Højland, Rikke Ebenhard, et al.
Publicado: (2015)

Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients
por: Bachler, Mirjam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_019c1i0idsvl3mvl84esgd81jl